Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | Finanzwire

Basculer en Français

8296	Companies
114902	Keywords
55332	Articles
62460	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 07/22/2024 at 13:05, 3 months 30 days ago

Protagonist Therapeutics to Participate in BTIG Virtual Biotechnology Conference 2024

Clinical Development Protagonist Therapeutics Rusfertide BTIG Conference Peptide-based NCEs
PRESS RELEASE

published on 07/22/2024 at 13:00, 3 months 30 days ago

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Protagonist Therapeutics, Inc. to participate in BTIG Virtual Biotechnology Conference. Company's lead drug candidate rusfertide in global Phase 3 development for polycythemia vera

Protagonist Therapeutics Rusfertide Polycythemia Vera BTIG Virtual Biotechnology Conference Phase 3 Development
BRIEF

published on 05/14/2024 at 22:10, 6 months 6 days ago

Protagonist Therapeutics to Present New Rusfertide Study Data at EHA Congress 2024

Clinical Study Protagonist Therapeutics Rusfertide Polycythemia Vera EHA Congress 2024
PRESS RELEASE

published on 05/14/2024 at 22:05, 6 months 6 days ago

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Protagonist Therapeutics to present rusfertide Phase 2 REVIVE study data at EHA Congress in Madrid. Study shows absence of QTc prolongation with rusfertide. Details on pipeline drugs and collaborations available on company's website

Clinical Development Collaborations Protagonist Therapeutics Rusfertide EHA Congress

Accesswire

Published on 11/21/2024 at 13:30, 14 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 14 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 44 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 44 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 44 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 29 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 9 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 29 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 38 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 44 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 46 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 24 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 59 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 59 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE